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Abstract Since 2001, cases of myelodysplastic syndromes
(MDSs) have been tracked by cancer registries. Examining
registry data in the USA, the reported age-adjusted incidence
of MDS per 100,000 was 3.3 per year for 2001–2003 and 4.9
per year for 2007–2011, with increases likely a result of grow-
ing awareness of reporting requirements. However, active
case-finding methods repeatedly demonstrate that
population-based registries have underestimated the incidence
of MDS due to underreporting and underdiagnosis. Using
keyword search strategies of electronic pathology reports or
other novel case capture methods, the true incidence of MDS
has been estimated between 5.3 and 13.1 per 100,000. Using
Medicare billing claims data, the incidence of MDS per 100,000
in patients aged ≥65 years has been estimated between 75 and
162. MDS prevalence is estimated to be 60,000 and –170,000
in the USA and projected to grow. Epidemiologic data can help
estimate the burden of MDS and expose unmet clinical needs.
For example, patients with MDS receiving transfusions had sig-
nificantly higher reported health care costs versus those that did
not (3-year mean of $88,824 vs $29,519). Epidemiologic data
also revealed that most MDS patients receiving transfusions do
not receive active therapies, despite strong evidence that
hypomethylating agents and lenalidomide significantly re-
duce transfusion burden. Other unmet needs identified by
epidemiologic studies include high need for treatment
options after failing first-line therapy and shared decision
making by older MDS patients.
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Introduction
The myelodysplastic syndromes (MDSs) are a diverse group
of clonal hematopoietic malignancies characterized by inef-
fective hematopoiesis, progressive bonemarrow (BM) failure,
cytogenetic and molecular abnormalities, and variable risk of
progression to acute myeloid leukemia (AML) [1–3]. Recent
reports showed that 5–10 % of older, apparently healthy indi-
viduals had acquired ≥1 myeloid gene mutation, whereas
younger individuals were much less likely to have acquired
clonal hematopoiesis with somatic mutations [4, 5]. These
results support the notion that the origin of MDS is tied to
aging and provide biological rationale for why MDS most
often presents in the seventh and eight decades of life [6, 7].
Clinically, patients with MDS often present with symptoms
related to peripheral cytopenias (e.g., fatigue, pallor, infec-
tions, bruising, bleeding), though theymay also be asymptom-
atic with abnormal blood counts found on routine evaluation
[8]. In elderly patients, cytopenias due to MDS—particularly
anemia—may be attributed to a more indolent etiology [9].
In the ninth edition of the International Classification of
Diseases (ICD-9), MDS was coded as a disease of blood and
blood-forming organs. In the tenth edition (ICD-10), MDS
was reclassified as a neoplasm and thus also included in the
third edition of ICD for Oncology (ICD-O-3), which provide
clarity in MDS epidemiology (Table 1). The accuracy of de-
termining MDS incidence and prevalence is crucial to allow
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for better understanding of the burden of MDS and appropri-
ate allocation of heath care resources.
Estimated Incidence of MDS
Population-Based Registries
Implementation of ICD-O-3 occurred worldwide in 2001,
from which time captured cases of MDS could be tracked
via cancer registries. The initial report from National Cancer
Institute Surveillance, Epidemiology, and End Results
(SEER) estimated the age-adjusted incidence of MDS per
100,000 to be 3.28, 3.37, and 3.56 in 2001, 2002, and 2003,
respectively (Table 2) [6]. Estimated rates per 100,000 per
year (2001–2003) in older patients increased from 10 in those
aged 65–69 years to 36.4 in those aged ≥85 years. Shortly
after, a more comprehensive report from the North American
Association of Central Cancer Registries (NAACCR) and
SEER estimated the age-adjusted incidence to be 3.27 per
100,000 per year (2001–2003) [10]. Rates per 100,000 per
year in older patients increased from 7.14 in those aged 60–
69 years to 35.49 in those aged ≥80 years. Estimated age-
adjusted incidence per 100,000 significantly increased by
year, from 3.1 in 2001 to 3.8 in 2004. Increasing incidence
estimates from 2001 to 2004 are likely a result of improved
awareness of the requirement of reporting resulting in rising
capture rates during these early years of ICD-O-3. However,
in the NAACCR/SEER study, only 4 % of MDS cases were
reported to registries from physicians’ offices [10]. Since
MDS is often diagnosed and managed outside of a hospital
setting, this surprisingly low percentage of cases reported
from outpatient clinics begged the question whether MDS
cases were being markedly underreported to population-
based cancer registries. Furthermore, since estimated MDS
incidence rates reported from various European countries
(including the UK [16], Germany [17, 18], Sweden [19],
France [20]), and Australia [21] were similar, underreporting
was suspected worldwide.
More recent data from SEER (2007–2011) estimated the
age-adjusted incidence to be 4.9 per 100,000 per year [11].
Estimated rates per 100,000 per year in elderly patients in-
creased from 13.5 in those aged 65–69 years to 63.6 in those
aged ≥85 years. Interestingly, the previous trend in estimated
rates from registry data increasing each year was no longer
observed, as the estimated age-adjusted incidence rate was
highest at 5.1 per 100,000 in 2007 and 2010 and lowest at
4.7 per 100,000 in 2011. Despite this apparent plateau, esti-
mates likely still underrepresent true incidence, as many cases
of MDS are not reported to cancer registries due to underdi-
agnosis, lack of recognition of MDS as a malignancy, limited
reporting by outpatient clinics, and changing guidelines for
coding of MDS cases [13, 14•, 22, 23]. It has been suggested
that passive case-finding methods such as registries may cap-
ture fewer patients with MDS than active case-finding
methods such as those using billing claims data, pathology,
cytogenetic, or other laboratory testing records [24].
Billing Claims-Based MDS Case Ascertainment
Use of Medicare billing claims data limits analyses to patients
aged ≥65 years; however, this cohort includes the great major-
ity of MDS cases. Medicare claims represent services provided
across specialties and care settings, which may address issues
with low registration of patients in outpatient settings. By ret-
rospective review of 2003 Medicare Standard Analytic Files
using ICD-9-Clinical Modification (CM) code 238.7x to iden-
tify patients with newly diagnosed MDS, Goldberg and col-
leagues estimated the incidence to be 162 per 100,000 in pa-
tients aged ≥65 years (114 in those aged 65–69 years to 204 in
those aged ≥80 years) [12]. This estimate is approximately
fourfold to fivefold higher compared to those from SEER and
Table 1 Coding of MDS using ICD-O-3 and ICD-9-CM
RAEB-2 RAEB-1 RARS RA RCMD RCMD-RS t-MDS NOS MDS 5q MDS NOS
ICD-O-3 9983a 9982 9980 9985 9987b 9986 9989
ICD-9-CM
Before Oct 2006 285.0 284.9 283.7
Oct 2006–Oct 2009 238.73 238.72 238.74c 238.75
Oct 2009–Oct 2015d 238.73 238.72 238.74c 238.75
5q 5q deletion syndrome, MDS myelodysplastic syndromes, NOS not otherwise specified, RA refractory anemia, RAEB refractory anemia with excess
blasts, RAEB-1 RAEB with 5–9 % blasts, RAEB-2 RAEB with 10–19 % blasts, RARS refractory anemia with ringed sideroblasts, RCMD refractory
anemia with multilineage dysplasia, RCMD-RS RCMD with ringed sideroblasts, t-MDS therapy-related MDS
a Prior to 2010, RAEB-in transformation had a unique code (9984) but is now grouped with RAEB-1
b Prior to 2010, t-MDS had a unique code (9987) but is now grouped with other therapy-related myeloid neoplasms
c Excludes patients with high-grade MDS with 5q deletion, which are coded as 238.72
dAs of October 1, 2015, ICD-10-CM with replace ICD-9-CM



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































274 Curr Hematol Malig Rep (2015) 10:272–281
NAACCR registry reports from similar time frames [6, 10].
Use of the nonspecific ICD-9-CM code 238.7x to identify
MDS cases could account for some this increase. ICD-9-CM
codes for billing are selected by treating physicians and serve as
their impression of the diagnosis rather than a confirmed path-
ological diagnosis, while registries rely on pathologically de-
rived ICD-O-3 codes. The ICD-9-CM has undergone several
changes in coding for MDS (Table 1), which impacts estimates
of MDS incidence. Therefore, publications using ICD-9-CM
should be clear about dates of examination and specific ICD-9-
CM codes used.
To address the specificity issue and improve case identifica-
tion, we developed four claims-based algorithms and assessed
algorithm validity using MDS cases registered by SEER [13].
The 1+ algorithm required a single claim with ICD-9-CM diag-
nosis of MDS, which aligned with the analysis from Goldberg
and colleagues [12]. The 2+ algorithm also required a second
claim 1–12 months after the first claim or death/hospice entry
within 3 months of the first claim. The 2+ BC algorithm also
required a blood count (BC) in the year before the first claim;
during this time period, guidelines for MDS diagnosis (World
Health Organization [WHO] and French-American-British
[FAB]) required a BC. Lastly, the 2+ BCBM algorithm also
required both a BC and bone marrow (BM) biopsy in the year
before the first claim; during this time period, guidelines for
MDS diagnosis (WHO/FAB) recommended but did not require
a BMbiopsy. Algorithmswere applied to the 2000–2008 SEER-
Medicare database. The 2+ BCBM algorithm was the most spe-
cific claims-based strategy and estimated an MDS incidence of
75 per 100,000 in patients ≥65 years in 2005—compared to 20
per 100,000 reported by SEER.
While a large sample size is a clear strength of claims-based
data capture, this approach limits the ability to examine details
of patient demographics and disease characteristics due to lack
of clinical information in administrative datasets. Additionally,
use of ICD-9-CM codes is limited to insured populations and
excludes patients enrolled in hospice or managed care organi-
zations that do not generate claims.
Population-Based Case Ascertainment
Using 2006 data from the Florida Cancer Data System (FCDS)
as a model, we devised a keyword search strategy to identify
cases of MDS among electronic pathology (e-path) reports re-
ceived by cancer registries from pathology laboratories [14•].
Since pathology laboratories are legislatively mandated to
transmit cancer pathology reports to paper-based state cancer
registries, our keyword strategy was expected to depend less on
the physical location of the patient’s diagnosis and identify
more potential cases. The search was restricted to electronic
reports with BM biopsy by querying on the term “marrow.” It
was found that 38 % of MDS cases identified from e-path
reports were not linked to an existing paper case in the FCDS
registry. Since paper-based registry data fromNAACCR/SEER
estimated the age-adjusted incidence in Florida to be 3.94 per
100,000 per year (2001–2003) [10], including the uncaptured
cases found by e-path reports extrapolated the estimated MDS
incidence to 6.4 per 100,000 per year in Florida and 5.3 per
100,000 per year in the entire USA.
Within a nonprofit health care system in westernWashington
State (2005–2006), MDS cases were identified via SEER regis-
try or relevant diagnostic code, followed by medical chart re-
view [15]. This region had reported the highest rates of MDS
among the SEER registry regions since mandatory reporting
began in 2001. This could reflect a true regional difference or
a false difference due to incomplete case ascertainment or un-
derdiagnosis varying by region. When combining cases from
SEER with those identified by medical chart review as “defi-
nite/probable” cases of MDS (BM biopsy or cytogenetics indi-
catingMDS or physician’s notes regardingMDS diagnosis), the
estimated age-adjusted incidence rate was 7.0 per 100,000 per
year. This was very similar to the 6.9 per 100,000 per year
reported using SEER alone, suggesting that reporting to SEER
in this region was nearly complete during this time frame.
However, incidence is likely still underestimated due to omis-
sion of cases that did not receive definitive diagnoses of MDS,
as the addition of those identified by medical chart review as
“possible”MDS cases (documentation that MDSwas suspected
or never definitively ruled out) raised the estimated age-adjusted
incidence rate to 10.2 per 100,000 per year.
A retrospective study of diagnostic and procedure data
from >300 hospitals in the Australian state of Victoria
(1998–2008) also showed a higher estimated incidence of
MDS (9.6 per 100,000) compared to Australia cancer registry
data (4.8 per 100.000) in 2007 [25]. Hospitalization data (from
Victorian Admitted Episode Dataset [VAED]) was subse-
quently linked with data from the statewide Victorian Cancer
Registry to examine patients with MDS from 2003 to 2010
[26•]. Cases of MDS were identified in VAED by diagnostic
code D46 from the Australia Modification of ICD-10. The
majority (86 %) of registry-reported cases were linked to
VAED data. For those not linked, most cases had been report-
ed to registry by pathology laboratories and patients may not
have been hospitalized. However, approximately half of
VAED cases were not reported to registry. Using registry data
only, the estimated age-adjusted incidence was 6.3 per 100,
000 per year and 44 per 100,000 per year in those aged
≥65 years. When pooling registry and VAED data, the esti-
mated age-adjusted incidence increased to 10.1 per 100,000
per year and 68 per 100,000 per year in those aged ≥65 years.
Next, a capture-recapture technique [27] was used to estimate
the extent of incomplete case ascertainment from the overlap-
ping registry and VAED datasets [26•]. With multinomial lo-
gistic regression applied, the estimated age-adjusted incidence
was further increased to 13.1 per 100,000 per year and 103 per
100,000 per year in those aged ≥65 years.
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With several methods tested and validated for capturing
cases of MDS, investigators have options. The choice of
methodology depends on the completeness of registry data
and available search fields. Going forward, new search engine
and mapping technologies could be applied to e-path reports
sent from diagnostic pathology laboratories to cancer
registries.
Estimated Prevalence of MDS
Accurate estimates of the number of people living with MDS
are difficult to make, and prevalence is scarcely reported.
Using Düsseldorf MDS Registry data from 1996 to 2005,
the overall prevalence of MDS was estimated to be 7 per
100,000 [18]. Some investigators have extrapolated these
German data and estimated ≈60,000 people living with
MDS in the USA [28, 29]. Considering that registry incidence
estimates are low, it is probable that this prevalence rate is also
an underestimate. Data from the third National Health and
Nutrition Examination Survey (1988–1994) showed that
10.6 % of the noninstitutionalized US population aged
≥65 years had anemia [30]. Approximately, a third of these
patients had unexplained anemia, 17 % of which had hemato-
logic features consistent with MDS (macrocytosis, neutrope-
nia, or thrombocytopenia). Sekeres and colleagues extrapolat-
ed this figure and estimated 170,000 people living with MDS
in the USA [28]. However, as there were no confirmatory BM
evaluations, this may be an overestimation.
With that in mind, another group retrospectively examined
BM from 322 patients at their Canadian center with unex-
plained cytopenias [31]. Of these, 23 % had a confirmed diag-
nosis of MDS and 10 % had a suspected diagnosis (element of
dyserythropoiesis, dysmegakaryopoiesis, or dysgranulopoiesis
detected but complete criteria for diagnosis not fulfilled or sec-
ondary causes not yet excluded). Extrapolating their data, they
estimated >90,000 people ≥65 years living with MDS in the
USA. However, measuring the frequency of MDS only in pa-
tients in whom a BM biopsy was indicated may also bias the
sample. The true prevalence of MDS in the USA likely lies
somewhere between the estimates of 60,000 and 170,000,
though prevalence will continue to rise as more active therapies
are available and patients are living longer with MDS.
Using Epidemiologic Tools to Estimate Burden
of MDS and Expose Unmet Needs
US Health Care Costs
To estimate health care resource utilization for patients with
MDS, analysts need accurate identification of MDS cases and
costs of medications, transfusions, procedures, and
hospitalizations associated with the disease. Using National
Comprehensive Cancer Network guidelines for treating pa-
tients with lower-risk MDS, the cost of drugs alone was
projected to average $63,577 per patient annually [32].
When examining actual costs (excluding outpatient prescrip-
tion drugs), a retrospective review of Medicare Standard
Analytic Files showed that Medicare payments for patients
with MDS were significantly higher than non-MDS
Medicare beneficiaries (means of $25,834 vs $6,810 in
2003, $19,180 vs $7,438 in 2004, and $18,758 vs $7,910 in
2005) [12].
In a multiple regression model, the presence of certain
baseline characteristics, clinical complications, and need for
transfusions were predictive, to varying degrees, of increases
in cost [33•]. With adjustment for baseline characteristics and
clinical complications, patient costs increased 77 % with dys-
pnea, 71 % with sepsis, 51 % with arrhythmia, 49 % with
bacteremia, 48 % with transfusions, 43 % with congestive
heart failure, 32 % with history of heart problems, and 30 %
with pneumonia. Of note, for patients who required transfu-
sions, this cost increase did not include the additional costs
related to transfusion administration. Patients receiving trans-
fusions also had greater use of hospital inpatient and outpa-
tient services and significantly higher Medicare costs (3-year
mean of $88,824 vs $29,519 for nontransfused patients) [33•].
Other studies have also examined the economic impact of
transfusion dependence (TD) and found markedly greater
use of inpatient and outpatient services and consequently sig-
nificantly higher costs [34, 35]. A literature search of Medline
and Embase found that reported annual medical costs per pa-
tient with MDS ranged from $9,840 to $19,811 for those who
were transfusion independent (TI) vs $29,608-$51,066 for
those who were TD [35].
Iron Overload
In patients with MDS, severe anemia resulting in red blood
cell (RBC)-TD was associated with increased mortality and
decreased quality of life [35–38]. Transfusions can lead to iron
overload, which associated with morbidities and adversely
impacted survival [36, 39]. A retrospective review of
Medicare Standard Analytic Files showed that during 3 years
of follow-up—even with age adjustment—MDS significantly
associated with increased risk of iron overload-related com-
plications (cardiac-related events, diabetes, dyspnea, hepatic
diseases, and infections) compared to the general Medicare
population [12]. Unsurprisingly, in the 40 % of patients that
received transfusions in this assessment, each of these com-
plications was significantly more prevalent than in non-
transfused patients with MDS. Patients receiving transfusions
also had significantly shorter overall survival (OS), increased
risk of transformation to AML, and increased risk of death.
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A separate retrospective review of a US health insurance
claims database (1997–2004) also showed that receipt of RBC
transfusions significantly increased the risk of iron overload-
related complications including cardiomyopathy/heart failure,
conduction/rhythm disorders, diabetes, and liver disease [40].
Hospitalization data from the Australian state of Victoria also
showed that RBC-TD patients had significantly higher rates of
congestive heart failure, bacterial and fungal infections, trans-
formation to AML, and sepsis as cause of death [25].
More recently, a retrospective claims review was per-
formed using the Optum Research Database (2007–2009),
which includes medical and pharmacy claims and eligibility
information from a national US health plan [41•]. Of 4351
patients with MDS identified, 1105 received ≥1 transfusion,
and transfusions were associated with higher risk of infection,
bleeding events, hospitalizations, and emergency room visits.
Patients who had active therapies but no transfusions had low-
er risks of these events than patients who had transfusions with
or without active therapies. In patients that had transfusions,
the risks of infection or bleeding events were similar whether
or not they had active therapy. Surprisingly, most patients (n=
886) receiving transfusions were not receiving active therapies
[41•], although active therapies such as azacitidine and
lenalidomide have been shown to significantly reduce RBC
transfusion burden [42, 43]. A study of lenalidomide asserted
that this reduction extends to cost burden—as the cost of
lenalidomide treatment was more than offset by the savings
related to reductions in TD and the associated complications
[44]. The low proportion of patients with MDS receiving ac-
tive therapies despite requiring transfusions exposes a clinical
practice mismatch worthy of further investigation. Are pa-
tients with MDS consistently being offered active treatments?
Are patients with MDS often refusing active treatments? Are
physicians uncomfortable treating patients with MDS using
agents that may transiently worsen cytopenias?
Active Treatment of Older Patients
Some older patients with MDS may not receive active
treatment due to age-related comorbidities and functional
impartment or the perception that therapies will not ex-
tend their survival. A prospective study of 43 patients
aged ≥60 years with high-risk MDS or AML showed that
treatment with intensive chemotherapy (IC) was signifi-
cantly associated with younger age but not related to per-
formance status, comorbidities, or quality of life [45].
Lack of treatment with IC in clinical practice is often
largely subjective, a result of patient or physician opinion,
or patient refusal.
However, newer lower-intensity therapies have dem-
onstrated efficacy and tolerability in the older popula-
tion. Azacitidine has been shown to significantly prolong
OS vs conventional care regimens (CCR; IC, low-dose
cytarabine, or best supportive care [BSC]) in patients with
high-risk MDS [42], including a subset of patients aged
≥75 years [46]. Decitabine has demonstrated significantly
improved rates of responses and hematologic improvement
in patients with MDS [47] and, in patients aged ≥60 years
with higher-risk MDS, significantly prolonged progression-
free survival and time to AML transformation [48]. With
lenalidomide treatment, the majority of patients with low-
er-risk, RBC-TD, del(5q) MDS achieve RBC-TI and cyto-
genetic response [49], at significantly higher rates than
with placebo [43]. A retrospective analysis of patients
≥75 vs <75 years old treated with lenalidomide showed
similar rates of response and time to progression to
AML [50].
A population-based study using the SEER-Medicare data-
base examined the use of hypomethylating agents (HMA)
azacitidine and decitabine in older patients (>65) with
MDS during the introductory years for these agents (N=
4416; diagnosed from 2001 to 2005) [51]. Overall, 11 % of
patients had receivedHMAs by the end of 2007 and frequency
of chemotherapy use was lower than HMA use throughout the
study period. Additionally, younger patients were more likely
to receive HMAs than older patients. A collection of six cross-
sectional surveys including 101 US hematologists and oncol-
ogists (June 2005–January 2007) showed that 27 % of recent-
ly diagnosed MDS patients (n=198, six surveys pooled) and
24–49 % of established MDS patients (n=4514, six surveys
separate) received supportive care only [52]. A retrospective
analysis of US claims data (January 2007–June 2010) includ-
ing patients aged ≥65 years with ≥2 claims with ICD-9-CM
diagnosis code for MDS (N=3577) showed that just 13 % had
received any active therapy forMDS [53]. Additionally, active
therapy use decreased with age—regardless of Charlson co-
morbidity index score. Together, these preliminary findings
show that despite the availability of active treatments for
MDS, a large proportion of older patients forgo treatment,
possibly due to patient or physician reluctance. This is an
unresolved issue that requires investigation.
Need for Therapies After HMA Failure
A population-based study using the SEER-Medicare database
showed that patients who received HMAs had significantly
improved 24-month survival versus patients that did not [54].
However, for patients who did not respond to HMAs, or those
who relapsed or progressed after response, prognosis was
poor [55–58]. Due to lack of treatment options, current guide-
lines suggest clinical trial or consideration of allogeneic stem
cell transplant in patients following HMA failure [59].
Guidelines also assert that HMA therapy should be continued
at least four to six cycles before assessing for failure. A lim-
ited case series showed that decitabine treatment following
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azacitidine failure yielded modest response rates (0–28 %)
that are typically brief [57, 60–63].
Recently, a US commercial health insurance claims da-
tabase was used to examine subsequent treatment patterns
for patients with MDS who had received HMAs [64, 65].
Patients with ICD-9-CM diagnosis code 238.7x were iden-
tified who used an HMA during 2009–2011. Patients were
eligible for second-line therapy after they had used the
same HMA for >7 months, discontinued treatment for
≥2 months, or switched to another HMA. Of 1366 patients
identified, 402 were eligible for second-line therapy.
Approximately 70 % and 30 % of patients received
azacitidine and decitabine in the first line, respectively,
and the mean all-cause and MDS-specific annual health
care costs during first-line treatment were $127,162 and
$80,673, respectively. Nearly half (48 %) of patients
stopped or switched HMA treatment at <5 treatment cy-
cles. The majority (61 %) of patients received BSC in the
second line; 30, 18, and 5 % received azacitidine,
decitabine, or lenalidomide, respectively. Following first-
line treatment failure, for those eligible for second-line
therapy, the mean all-cause 6-month health care cost was
$76,945. A separate retrospective study of patients with
ICD-9-CM code 238.7x from 2009 to 2011 also showed
that approximately 70 % of patients treated with HMAs
received <6 cycles; 32 % stopped therapy after only 1
cycle [66]. These results highlight a large and costly unmet
need in patients with MDS who fail first-line HMA treat-
ment. There is a clear and urgent need for second-line
agents to treat patients with MDS.
Risk Assessment in Patients with MDS
The treatment paradigm for patients with MDS depends
upon prognostic risk assessment [7, 59, 67–69]. However,
applying prognostic models to epidemiologic data is not
possible, as clinical and laboratory variables such as hemo-
globin level or genomic mutations are often not captured in
population-based registries or billing claims datasets.
Recently, the 2001–2007 SEER-Medicare dataset was used
to derive a completely claims-based prognostic scoring sys-
tem termed the SEER-Medicare MDS Risk Score
(SMMRS) [70]. Risk predictors in SMMRS were cytope-
nias, MDS pathologic subtype, age at diagnosis, Charlson
comorbidity index score, presence of acute hospitaliza-
tions, and RBC- and/or platelet-TD. The MDS clinical da-
tabase from the Dana-Farber Cancer Institute was used for
external validation of the SMMRS and showed that risk
stratification by SMMRS was not significantly different
than by International Prognostic Index score [67]. While
the SMMRS is not intended for clinical use, it has potential
utility in research using the SEER-Medicare dataset, for
example, to help address potential impacts of confounding
due to baseline disease risk.
Identifying Populations at Risk for Developing MDS
With approximately 30 % of MDS cases arising after che-
motherapy or radiotherapy (RT) treatment of an antecedent
cancer [71], there is urgent need to identify patients with
solid tumors that are at higher risk for therapy-related
MDS. Recently, Mukherjee and colleagues combined reg-
istry databases and discovered that modern RT techniques
did not increase the risk of developing MDS in patients
with prior history of prostate cancer [72, 73]. These results
added to mounting evidence that modern RT alone may not
trigger therapy-related MDS, leaving investigators to focus
on other factors such as age, DNA repair activity, and
health of BM microenvironment.
Conclusions
Since 2001, cases of MDS have been legislatively man-
dated for tracking in cancer registries. Registry data in
the USA and elsewhere have provided estimates of MDS
incidence; however, billing claims data and other active
case-finding methods have repeatedly demonstrated that
population-based registries have underestimated the inci-
dence of MDS. This underreporting highlights the urgent
need for deeper investment in state cancer registries.
Incidence estimates are further hindered by underdiagno-
sis of MDS in older patients with cytopenias. With rap-
idly evolving estimates of incidence, estimating preva-
lence is difficult, particularly with the addition of active
therapies that can help patients with MDS live longer. As
epidemiologic data for patients with MDS becomes more
robust, it has the potential to be used to identify and/
or help address unmet needs for patients
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